Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting P2Y12 platelet inhibitor. It is a member of the cyclopentyltriazolopyrimidine (CPTP) class.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
* Prevention of stent thrombosis in patients with ACS treated with percutaneous coronary intervention (PCI).
## Adult Dosing
* **Acute Coronary Syndrome (ACS):** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily.
* **Post-MI (≥ 1 year after ACS or PCI):** If ticagrelor was initiated in the ACS setting, continue at 90 mg orally twice daily. For patients who have had an MI more than 1 year ago and are at high risk for occlusive vascular events, consider 60 mg orally twice daily.
* **Maintenance dose for high-risk post-MI patients:** 60 mg orally twice daily.
* **Maximum dose:** Not explicitly defined, but commonly used doses are 180 mg (loading), 90 mg BID, and 60 mg BID.
## Pediatric Dosing
Ticagrelor is not approved for use in pediatric patients.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is recommended for mild to severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Most Common:** Bleeding (including major and minor), dyspnea.
* **Serious:** Life-threatening bleeding, ventricular pauses, bradyarrhythmias.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease ticagrelor exposure.
* **Other Antiplatelet Agents/Anticoagulants:** Increased risk of bleeding. Use with caution and monitor closely for bleeding.
* **Aspirin:** Ticagrelor plus aspirin is generally used in ACS, but the optimal duration and dose of aspirin can vary. Long-term high-dose aspirin may increase bleeding risk with ticagrelor.
* **Rh-HMG-CoA Reductase Inhibitors (Statins):** Concomitant use with simvastatin or atorvastatin may increase statin exposure. Doses of simvastatin >40 mg and atorvastatin >80 mg should be avoided.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Cardiac Rhythm:** Monitor for ventricular pauses, especially in patients with a history of bradyarrhythmias.
## Clinical Pearls
* Ticagrelor should be administered as soon as possible after ACS diagnosis.
* Unlike clopidogrel, ticagrelor is a reversible P2Y12 inhibitor and does not require metabolic activation.
* Dyspnea is a common side effect and is usually not clinically significant but should be evaluated.
* Discontinuation of ticagrelor increases the risk of thrombotic events. If ticagrelor must be discontinued, it should be done as soon as medically possible.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.*
